News from Eli Lilly and Company Limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Oct 18, 2017, 06:45 ET Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

Eli Lilly and Company (NYSE: LLY) and CureVac AG have announced a global immuno-oncology collaboration focused on the development and...


Oct 16, 2017, 14:45 ET Lilly Declares Fourth-Quarter 2017 Dividend

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2017 of $0.52 per share on...


Oct 16, 2017, 06:45 ET Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA® (ramucirumab) Phase 3 Subgroup Analysis

New subgroup analysis from Eli Lilly and Company's (NYSE: LLY) Phase 3 REVEL trial of CYRAMZA® (ramucirumab) in advanced non-small cell lung cancer...


Oct 12, 2017, 06:45 ET FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio™ (abemaciclib) as Initial Treatment of Advanced Breast Cancer

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for its...


Oct 10, 2017, 06:45 ET Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer

Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 JUNIPER study evaluating Verzenio™ (abemaciclib), a cyclin-dependent kinase...


Oct 06, 2017, 13:00 ET Lilly MONARCH 3 Study Published in Journal of Clinical Oncology Demonstrates Benefit of Verzenio™ (abemaciclib) Plus NSAI in Advanced Breast Cancer

Eli Lilly and Company (NYSE: LLY) today announced that interim results from the double-blind, placebo-controlled Phase 3 MONARCH 3 study evaluating...


Oct 05, 2017, 16:13 ET U.S. Patent and Trademark Office Rules In Lilly's Favor On Alimta Vitamin Regimen Patent

Eli Lilly and Company (NYSE: LLY) today announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (PTO) has ruled in...


Oct 05, 2017, 15:48 ET Additional Delivery of Insulin Ready for Distribution in Puerto Rico

Today, a new shipment of commercial medicines, including more than 36,000 vials and pens of insulin, arrived in Puerto Rico. The delivery by Eli...


Oct 04, 2017, 09:00 ET Humalog® Junior KwikPen® Now Available in the U.S. for People with Diabetes

Humalog® Junior KwikPen® [insulin lispro injection 100 units/mL] is now available by prescription for the treatment of diabetes in the U.S. This...


Oct 02, 2017, 10:00 ET Lilly Confirms Date and Conference Call for Third-Quarter 2017 Financial Results Announcement

Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2017 on Tuesday, October 24, 2017. Lilly will also...


Sep 29, 2017, 06:45 ET Lilly Announces Senior Leadership Appointments for Finance, Research & Development and Manufacturing

Eli Lilly and Company (NYSE: LLY) today announced a number of leadership changes, promoting several experienced Lilly leaders to executive roles,...


Sep 25, 2017, 08:30 ET Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

In an effort to improve health outcomes of people with type 2 diabetes, Geisinger and Boehringer Ingelheim, on behalf of its diabetes alliance with...


Sep 14, 2017, 09:00 ET Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced new safety and efficacy data from a Phase 2 study of...


Sep 12, 2017, 06:59 ET Jardiance® (empagliflozin) tablets reduced risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease independent of background blood sugar control

New analyses of the landmark EMPA-REG OUTCOME® trial showed that Jardiance® (empagliflozin) tablets reduced the risk of cardiovascular death in...


Sep 11, 2017, 09:00 ET Lilly to Present New Data for Olumiant® (baricitinib) and Taltz® (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress

Eli Lilly and Company (NYSE: LLY) announced that data across its immunology portfolio will be presented at the annual European Academy of...


Sep 10, 2017, 02:26 ET Lilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer

At the European Society for Medical Oncology (ESMO) 2017 Congress today, Phase 3 RANGE data from Eli Lilly and Company (NYSE: LLY) were presented...


Sep 09, 2017, 08:00 ET IHC 2017: Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine

Eli Lilly and Company (NYSE: LLY) will present key primary and secondary endpoint data for lasmiditan, an investigational, oral, first-in-class...


Sep 08, 2017, 06:45 ET IHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results for up to 12 Months in Patients with Migraine

Eli Lilly and Company (NYSE: LLY) announced today that treatment with self-administered galcanezumab for up to 12 months demonstrated a positive...


Sep 07, 2017, 09:15 ET Lilly Takes Steps to Streamline Business, Invest in New Medicines and Drive Growth

Eli Lilly and Company (NYSE: LLY) today announced actions to streamline operations to more efficiently focus resources on developing new medicines...


Sep 06, 2017, 06:45 ET Lilly to Present New Data for Galcanezumab and Lasmiditan at the 18th Congress of the International Headache Society (IHC)

Eli Lilly and Company (NYSE: LLY) announced today it will present new data for galcanezumab and lasmiditan, two investigational treatments for...


Aug 30, 2017, 06:45 ET Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that, after discussions with the U.S. Food and Drug...


Aug 29, 2017, 06:45 ET New Phase 3 Data for Abemaciclib and Ramucirumab Presented at ESMO 2017 Congress

Eli Lilly and Company (NYSE: LLY) will showcase new data across six different tumor types at the European Society for Medical Oncology (ESMO) 2017...


Aug 28, 2017, 14:00 ET Lilly to Participate in Morgan Stanley Global Healthcare Conference

Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2017. Derica Rice, Lilly's...


Aug 04, 2017, 06:45 ET Lilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of Migraine

Eli Lilly and Company (NYSE: LLY) announced today that lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of...


Jul 31, 2017, 09:00 ET Boehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight the increasingly important role of cardiologists in reducing cardiovascular risk and cardiovascular death in people with type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the companies will support an American College of Cardiology (ACC)...